Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Fátima Cardoso, A. Costa, Larry Norton, et al.
The Breast (2014) Vol. 23, Iss. 5, pp. 489-502
Open Access | Times Cited: 314

Showing 1-25 of 314 citing articles:

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso, A. Costa, Elżbieta Senkus, et al.
Annals of Oncology (2016) Vol. 28, Iss. 1, pp. 16-33
Open Access | Times Cited: 1927
Breast cancer
Nadia Harbeck, Michael Gnant
The Lancet (2016) Vol. 389, Iss. 10074, pp. 1134-1150
Closed Access | Times Cited: 1863
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, et al.
New England Journal of Medicine (2016) Vol. 375, Iss. 18, pp. 1738-1748
Open Access | Times Cited: 1668
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge, Masakazu Toi, Patrick Neven, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 25, pp. 2875-2884
Closed Access | Times Cited: 1370
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Fátima Cardoso, Shani Paluch‐Shimon, Elżbieta Senkus, et al.
Annals of Oncology (2020) Vol. 31, Iss. 12, pp. 1623-1649
Open Access | Times Cited: 1075
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Fátima Cardoso, Elżbieta Senkus, A. Costa, et al.
Annals of Oncology (2018) Vol. 29, Iss. 8, pp. 1634-1657
Open Access | Times Cited: 1055
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Alessandra Gennari, Fabrice André, Carlos H. Barrios, et al.
Annals of Oncology (2021) Vol. 32, Iss. 12, pp. 1475-1495
Open Access | Times Cited: 834
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
J.F.R. Robertson, Igor Bondarenko, Ekaterina Trishkina, et al.
The Lancet (2016) Vol. 388, Iss. 10063, pp. 2997-3005
Open Access | Times Cited: 520
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Marleen Keyaerts, Catarina Xavier, Johannes Heemskerk, et al.
Journal of Nuclear Medicine (2015) Vol. 57, Iss. 1, pp. 27-33
Open Access | Times Cited: 379
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 19, pp. 2141-2148
Open Access | Times Cited: 327
Brain Metastases in Newly Diagnosed Breast Cancer
Allison Martin, Daniel Cagney, Paul J. Catalano, et al.
JAMA Oncology (2017) Vol. 3, Iss. 8, pp. 1069-1069
Open Access | Times Cited: 262
Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015)
Fátima Cardoso, Danielle Spence, Shirley Mertz, et al.
The Breast (2018) Vol. 39, pp. 131-138
Closed Access | Times Cited: 241
3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso, A. Costa, Elżbieta Senkus, et al.
The Breast (2016) Vol. 31, pp. 244-259
Open Access | Times Cited: 229
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
Matthew J. Ellis, Antonio Llombart‐Cussac, David Feltl, et al.
Journal of Clinical Oncology (2015) Vol. 33, Iss. 32, pp. 3781-3787
Open Access | Times Cited: 222
Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
Marc C. Chamberlain, Christina S. Baik, Vijayakrishna K. Gadi, et al.
Neuro-Oncology (2016) Vol. 19, Iss. 1, pp. i1-i24
Open Access | Times Cited: 201
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
Kathy D. Miller, Javier Cortés, Sara A. Hurvitz, et al.
BMC Cancer (2016) Vol. 16, Iss. 1
Open Access | Times Cited: 139
Optimal management of hormone receptor positive metastatic breast cancer in 2016
Tomás Reinert, Carlos H. Barrios
Therapeutic Advances in Medical Oncology (2015) Vol. 7, Iss. 6, pp. 304-320
Open Access | Times Cited: 127
Prognostic Value of Intrinsic Subtypes in Hormone Receptor–Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib
Aleix Prat, Maggie C.U. Cheang, Patricia Galván, et al.
JAMA Oncology (2016) Vol. 2, Iss. 10, pp. 1287-1287
Open Access | Times Cited: 112
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Brain Metastases Working Group
Nancy U. Lin, Tatiana M. Prowell, Antoinette R. Tan, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 33, pp. 3760-3773
Closed Access | Times Cited: 103
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
Peter Vuylsteke, Manon Huizing, Katarína Petráková, et al.
Annals of Oncology (2016) Vol. 27, Iss. 11, pp. 2059-2066
Open Access | Times Cited: 99
MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study
Qing Yuan Zhang, Tao Sun, Yong Yin, et al.
Therapeutic Advances in Medical Oncology (2020) Vol. 12
Open Access | Times Cited: 73
ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases
Joanne Van der Velden, Jonas Willmann, Mateusz Spałek, et al.
Radiotherapy and Oncology (2022) Vol. 173, pp. 197-206
Open Access | Times Cited: 59
Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches
Farah Raheem, Suganya Arunachalam Karikalan, Felipe Batalini, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16198-16198
Open Access | Times Cited: 25
The Influence of Tumor-Specific Markers in Breast Cancer on Other Blood Parameters
Vlad Bogdan Varzaru, Anca-Elena Eftenoiu, Daliborca Cristina Vlad, et al.
Life (2024) Vol. 14, Iss. 4, pp. 458-458
Open Access | Times Cited: 7
Breast Cancer Under Age 40: a Different Approach
Domen Ribnikar, Joana Ribeiro, David Pinto, et al.
Current Treatment Options in Oncology (2015) Vol. 16, Iss. 4
Closed Access | Times Cited: 85
Page 1 - Next Page

Scroll to top